Evidence map›Paper›PMID 34848426›Full record

ArticleBMJ case reports2021

Miller-Fisher Syndrome and Guillain-Barre Syndrome overlap syndrome in a patient post Oxford-AstraZeneca SARS-CoV-2 vaccination.

Yew Li Dang, Alexander Bryson

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. The spectrum of anti-GQ1B antibody syndrome: beyond Miller Fisher syndrome and Bickerstaff brainstem encephalitis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Review
  8. Review
  9. [Miller-Fisher/Guillain-Barré overlap syndrome following COVID-19 vaccination].Revista medica del Instituto Mexicano del Seguro Social · 2024
    Article
  10. Review
  11. Article
  12. Neuro-Ophthalmic Complications of COVID-19 Infection and Vaccination.Advances in ophthalmology and optometry · 2023
    Review
  13. Ocular motility disorders following coronavirus disease-19 vaccination.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Article
  14. Review
  15. Article
  16. Co-VAN study: COVID-19 vaccine associated neurological diseases- an experience from an apex neurosciences centre and review of the literature.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2023
    Review
  17. Post-COVID-19 Vaccination CNS Magnetic Resonance Imaging Findings: A Systematic Review.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2023
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Yew Li DangDepartment of Neurology, Box Hill Hospital, Box Hill, Victoria, Australia.ORCID http://orcid.org/0000-0002-0570-5398
Alexander BrysonDepartment of Neurology, Austin Health, Heidelberg, Victoria, Australia alex.bryson@austin.org.au.ORCID http://orcid.org/0000-0002-0033-8197
Austin Health · AUBox Hill Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a patient who developed bilateral oculomotor nerve palsy, ataxia, facial diplegia and lower limb weakness 2 weeks post-Oxford-AstraZeneca SARS-CoV2 vaccination, consistent with Miller-Fisher syndrome (MFS) and Guillain-Barre syndrome (GBS) overlap syndrome. Although some features of the patient's presentation were typical of recently reported cases of a rare GBS variant post-Oxford-AstraZeneca vaccination, including severe facial weakness and a lack of respiratory involvement, to our knowledge this is the first reported case of MFS associated with SARS-CoV2 vaccination. While postvaccination GBS remains rare, it appears to have a favourable prognosis, and recognising this entity is therefore important for patient counselling and monitoring for potential complications.

Indexed as

COVID-19Guillain-Barre SyndromeMiller Fisher SyndromeCOVID-19 VaccinesHumansRNA, ViralSARS-CoV-2VaccinationCOVID-19 VaccinesRNA, ViralCOVID-19cranial nervesneurologyperipheral nerve disease

Identifiers

PMID34848426
PMCPMC8634230
OpenAlexW3215983263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.